Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism

Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism

Source: 
Fierce Biotech
snippet: 

Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. With its lead program under clinical hold, the microbiome specialist has pulled out of a planned study in chronic hepatitis B.